{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:52:02Z","timestamp":1792479122924,"version":"4.5.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.eprac.2026.01.024","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T07:49:17Z","timestamp":1769759357000},"page":"990-1000","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Glucocorticoid-Induced Hyperglycemia in Patients With Cancer: Mechanisms, Clinical Implications, and Management Strategies"],"prefix":"10.1016","volume":"32","author":[{"given":"Luana Lury","family":"Morikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Nery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9146-4606","authenticated-orcid":false,"given":"Marcos Tadashi Kakitani","family":"Toyoshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.eprac.2026.01.024_bib1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11892-019-1283-6","article-title":"Hospitalization as an opportunity to optimize glycemic control in oncology patients","volume":"19","author":"Hiestand","year":"2019","journal-title":"Curr Diab Rep"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.024_bib2","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.4143\/crt.2015.464","article-title":"A pilot study evaluating steroid-induced diabetes after antiemetic dexamethasone therapy in chemotherapy-treated cancer patients","volume":"48","author":"Jeong","year":"2016","journal-title":"Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.024_bib3","article-title":"Effects of glucocorticoids on interstitial glucose concentrations in individuals with hematologic cancer and without known diagnosis of diabetes: a pilot study","volume":"20","author":"Toyoshima","year":"2022","journal-title":"Einstein (Sao Paulo)"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.024_bib4","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.clinthera.2023.11.013","article-title":"The effect of different types of oral or intravenous corticosteroids on capillary blood glucose levels in hospitalized inpatients with and without diabetes","volume":"46","author":"Limbachia","year":"2024","journal-title":"Clin Ther"},{"issue":"8","key":"10.1016\/j.eprac.2026.01.024_bib5","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.4239\/wjd.v6.i8.1073","article-title":"Steroid hyperglycemia: prevalence, early detection and therapeutic recommendations: a narrative review","volume":"6","author":"Tamez-P\u00e9rez","year":"2015","journal-title":"World J Diabetes"},{"key":"10.1016\/j.eprac.2026.01.024_bib6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.diabres.2018.03.006","article-title":"Steroid-induced hyperglycemia: an underdiagnosed problem or clinical inertia? A narrative review","volume":"139","author":"Bonaventura","year":"2018","journal-title":"Diabetes Res Clin Pract Elsevier Ireland Ltd"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.024_bib7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.diabres.2012.12.023","article-title":"The high incidence of steroid-induced hyperglycaemia in hospital","volume":"99","author":"Fong","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.024_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/10547738241291272","article-title":"Management of glucocorticoid-induced hyperglycemia in cancer patients: a feasibility study","volume":"34","author":"Wright","year":"2025","journal-title":"Clin Nurs Res"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.024_bib9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11892-015-0581-x","article-title":"Hyperglycemia in patients with hematologic malignancies","volume":"15","author":"Healy","year":"2015","journal-title":"Curr Diab Rep"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.024_bib10","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1515\/jtim-2016-0011","article-title":"A little help from steroids in oncology","volume":"4","author":"Lossignol","year":"2016","journal-title":"J Transl Int Med"},{"issue":"10","key":"10.1016\/j.eprac.2026.01.024_bib11","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.3390\/jcm10102154","article-title":"A practical guide for the management of steroid induced hyperglycaemia in the hospital","volume":"10","author":"Aberer","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.024_bib12","doi-asserted-by":"crossref","DOI":"10.1111\/dme.14636","article-title":"A guideline for the outpatient management of glycaemic control in people with cancer","volume":"39","author":"Joharatnam-Hogan","year":"2022","journal-title":"Diabetic Med"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.024_bib13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13098-022-00949-z","article-title":"The 2021\u20132022 position of Brazilian diabetes society on insulin therapy in type 1 diabetes: an evidence-based guideline to clinical practice","volume":"14","author":"Silva J\u00fanior","year":"2022","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.024_bib14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1710-1492-9-30","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.eprac.2026.01.024_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103826","volume":"180","author":"Faggiano","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"10.1016\/j.eprac.2026.01.024_bib16","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.eprac.2022.07.014","article-title":"Glucocorticoid-induced hyperglycemia including dexamethasone-associated hyperglycemia in COVID-19 infection: a systematic review","volume":"28","author":"Brooks","year":"2022","journal-title":"Endocr Pract"},{"issue":"9","key":"10.1016\/j.eprac.2026.01.024_bib17","first-page":"1193","article-title":"The periodic health examination. Canadian task force on the periodic health examination","volume":"121","year":"1979","journal-title":"Can Med Assoc J"},{"issue":"9","key":"10.1016\/j.eprac.2026.01.024_bib18","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41574-022-00683-6","article-title":"Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions","volume":"18","author":"Li","year":"2022","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.024_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22020623","article-title":"Molecular mechanisms of glucocorticoid-induced insulin resistance","volume":"22","author":"Beaupere","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.024_bib20","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/MAJ.0b013e31828a6a01","article-title":"Glucocorticoid-induced hyperglycemia","volume":"345","author":"Kwon","year":"2013","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.eprac.2026.01.024_bib21","series-title":"Glucocorticoid Signaling From Molecules to Mice to Man","first-page":"99","article-title":"Regulation of glucose homeostasis by glucocorticoids","author":"Kuo","year":"2015"},{"issue":"Supplement_1","key":"10.1016\/j.eprac.2026.01.024_bib22","doi-asserted-by":"crossref","first-page":"S339","DOI":"10.2337\/dc26-S016","article-title":"16. Diabetes care in the hospital: standards of care in Diabetes\u20142026","volume":"49","author":"Bajaj","year":"2026","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2026.01.024_bib23","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.cmet.2021.06.004","article-title":"Individual-specific functional epigenomics reveals genetic determinants of adverse metabolic effects of glucocorticoids","volume":"33","author":"Hu","year":"2021","journal-title":"Cell Metab"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.024_bib24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.diabres.2015.02.010","article-title":"Risk factors for the development of glucocorticoid-induced diabetes mellitus","volume":"108","author":"Katsuyama","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"10.1016\/j.eprac.2026.01.024_bib25","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.2337\/dc23-0353","article-title":"Type 2 diabetes polygenic score predicts the risk of glucocorticoid-induced hyperglycemia in patients without diabetes","volume":"46","author":"Deutsch","year":"2023","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.024_bib26","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3803\/EnM.2017.32.2.180","article-title":"Glucocorticoid-induced diabetes mellitus: an important but overlooked problem","volume":"32","author":"Suh","year":"2017","journal-title":"Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.eprac.2026.01.024_bib27","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1111\/dom.14808","article-title":"The absolute risk of incident type 2 diabetes following exposure to systemic corticosteroids in selected steroid-related and phenotypic groups","volume":"24","author":"Ambery","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"Supplement_1","key":"10.1016\/j.eprac.2026.01.024_bib28","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.2337\/dc26-S002","article-title":"2. Diagnosis and classification of diabetes: standards of care in Diabetes\u20142026","volume":"49","author":"Bajaj","year":"2026","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.eprac.2026.01.024_bib29","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1111\/dme.13770","article-title":"Diurnal profile of interstitial glucose following dexamethasone prophylaxis for chemotherapy treatment of gynaecological cancer","volume":"35","author":"Lyall","year":"2018","journal-title":"Diabetic Med"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.024_bib30","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s12020-024-03841-0","article-title":"Continuous glucose monitoring profile in COVID-19 patients with and without diabetes receiving methylprednisolone","volume":"86","author":"He","year":"2024","journal-title":"Endocrine"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.024_bib31","first-page":"459","article-title":"Hyperglycemia and cancer: a state-of-the-science review","volume":"46","author":"Hammer","year":"2019","journal-title":"Oncol Nurs Forum"},{"issue":"8","key":"10.1016\/j.eprac.2026.01.024_bib32","first-page":"563","article-title":"Optimal hyperglycemia thresholds in patients undergoing chemotherapy: a cross sectional study of oncologists\u2019 practices","volume":"32","author":"Salgado","year":"2024","journal-title":"Support Care Cancer"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.024_bib33","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s13300-023-01393-6","article-title":"Practical guide to glucocorticoid induced hyperglycaemia and diabetes","volume":"14","author":"Barker","year":"2023","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.eprac.2026.01.024_bib34","article-title":"Wearable diabetes technology for hospitalized people with diabetes and end-stage kidney disease, peripartum state, and steroid use","author":"Agarwal","year":"2025","journal-title":"J Diabetes Sci Technol"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.024_bib35","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11892-021-01435-y","article-title":"Patient-centered diabetes care of cancer patients","volume":"21","author":"Kotwal","year":"2021","journal-title":"Curr Diab Rep"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.024_bib36","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.eprac.2024.09.013","article-title":"High frequency of severe hyperglycemia observed during intensive hematologic care: a prospective study using continuous glucose monitoring","volume":"30","author":"Tienstra","year":"2024","journal-title":"Endocr Pract"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.024_bib37","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3803\/EnM.2024.1951","article-title":"Glucocorticoid-induced hyperglycemia: a neglected problem","volume":"39","author":"Cho","year":"2024","journal-title":"Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.024_bib38","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1177\/1060028017728297","article-title":"Optimizing the treatment of steroid-induced hyperglycemia","volume":"52","author":"Wallace","year":"2018","journal-title":"Ann Pharmacother"},{"issue":"11","key":"10.1016\/j.eprac.2026.01.024_bib39","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.rmed.2014.08.006","article-title":"The impact of corticosteroid treatment on hemoglobin A1C levels among patients with type-2 diabetes with chronic obstructive pulmonary disease exacerbation","volume":"108","author":"Habib","year":"2014","journal-title":"Respir Med"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.024_bib40","doi-asserted-by":"crossref","first-page":"R207","DOI":"10.1530\/EJE-18-0315","article-title":"Management of endocrine disease: critical review of the evidence underlying management of glucocorticoid-induced hyperglycaemia","volume":"179","author":"Radhakutty","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.eprac.2026.01.024_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinsp.2023.100240","article-title":"Fructosamine and glycated hemoglobin as biomarkers of glycemic control in people with type 2 diabetes mellitus and cancer (GlicoOnco study)","volume":"78","author":"Toyoshima","year":"2023","journal-title":"Clinics"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.024_bib42","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S2213-8587(20)30021-8","article-title":"Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial","volume":"8","author":"Pernicova","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.eprac.2026.01.024_bib43","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/dme.13675","article-title":"Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group","volume":"35","author":"Roberts","year":"2018","journal-title":"Diabetic Med"},{"issue":"15","key":"10.1016\/j.eprac.2026.01.024_bib44","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.2174\/1389201020666190102145305","article-title":"Hyperglycemia and diabetes induced by glucocorticoids in nondiabetic and diabetic patients: revision of literature and personal considerations","volume":"19","author":"Elena","year":"2019","journal-title":"Curr Pharm Biotechnol"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.024_bib45","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0889-857X(05)70083-1","article-title":"Drug selection and the management of corticosteroid-related diabetes mellitus","volume":"25","author":"Hoogwerf","year":"1999","journal-title":"Rheum Dis Clin North America"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.024_bib46","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0168-8227(02)00127-4","article-title":"Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes","volume":"58","author":"Willi","year":"2002","journal-title":"Diabetes Res Clin Pract"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.024_bib47","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1111\/j.1600-6143.2004.00613.x","article-title":"Pioglitazone in the management of diabetes mellitus after transplantation","volume":"4","author":"Luther","year":"2004","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.eprac.2026.01.024_bib48","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.metabol.2015.02.005","article-title":"Thiazolidinediones attenuate lipolysis and ameliorate dexamethasone-induced insulin resistance","volume":"64","author":"He","year":"2015","journal-title":"Metabolism"},{"issue":"19","key":"10.1016\/j.eprac.2026.01.024_bib49","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.2169\/internalmedicine.8296-16","article-title":"The assessment of the efficacy of dipeptidyl Peptidase-4 inhibitors in patients with glucocorticoid-induced diabetes by continuous glucose monitoring","volume":"56","author":"Yata","year":"2017","journal-title":"Intern Med"},{"key":"10.1016\/j.eprac.2026.01.024_bib50","doi-asserted-by":"crossref","first-page":"587","DOI":"10.12659\/MSM.889872","article-title":"Alogliptin improves steroid-induced hyperglycemia in treatment-na\u00efve Japanese patients with chronic kidney disease by decrease of plasma glucagon levels","volume":"20","author":"Ohashi","year":"2014","journal-title":"Med Sci Monitor"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.024_bib51","doi-asserted-by":"crossref","first-page":"479","DOI":"10.14740\/jocmr2153w","article-title":"Effects of 6-Month sitagliptin treatment on metabolic parameters in diabetic patients taking oral glucocorticoids: a retrospective cohort study","volume":"7","author":"Katsuyama","year":"2015","journal-title":"J Clin Med Res"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.024_bib52","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1530\/EJE-13-0610","article-title":"Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial","volume":"170","author":"van Genugten","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.024_bib53","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2337\/dc10-1677","article-title":"Glucagon-like Peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans","volume":"34","author":"van Raalte","year":"2011","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.024_bib54","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1111\/dom.13209","article-title":"Dapagliflozin for prednisone-induced hyperglycaemia in acute exacerbation of chronic obstructive pulmonary disease","volume":"20","author":"Gerards","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.eprac.2026.01.024_bib55","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1210\/clinem\/dgac278","article-title":"Management of hyperglycemia in hospitalized adult patients in non-critical care settings: an Endocrine Society Clinical Practice Guideline","volume":"107","author":"Korytkowski","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.024_bib56","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/CCM.0000000000006173","article-title":"Society of Critical Care Medicine Guidelines on glycemic control for critically ill children and adults 2024: executive summary","volume":"52","author":"Honarmand","year":"2024","journal-title":"Crit Care Med"},{"issue":"8","key":"10.1016\/j.eprac.2026.01.024_bib57","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1007\/s00125-024-06183-8","article-title":"Hyperglycaemic crises in adults with diabetes: a consensus report","volume":"67","author":"Umpierrez","year":"2024","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.024_bib58","doi-asserted-by":"crossref","first-page":"836","DOI":"10.4103\/ijem.IJEM_226_17","article-title":"Comparison of two protocols in the management of glucocorticoid-induced hyperglycemia among hospitalized patients","volume":"21","author":"Lakhani","year":"2017","journal-title":"Indian J Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.024_bib59","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s13300-018-0468-3","article-title":"Glycemic control in hospitalized patients with diabetes receiving corticosteroids using a neutral protamine hagedorn insulin protocol: a randomized clinical trial","volume":"9","author":"Khowaja","year":"2018","journal-title":"Diabetes Ther"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.024_bib60","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4158\/EP15818.OR","article-title":"Hospital insulin protocol aims for glucose control in glucocorticoid-induced hyperglycemia","volume":"22","author":"Grommesh","year":"2016","journal-title":"Endocr Pract"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.024_bib61","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/jhm.874","article-title":"Pilot study of using neutral protamine hagedorn insulin to counteract the effect of methylprednisolone in hospitalized patients with diabetes","volume":"6","author":"Seggelke","year":"2011","journal-title":"J Hosp Med"},{"issue":"10","key":"10.1016\/j.eprac.2026.01.024_bib62","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/dom.12694","article-title":"Add-on treatment with intermediate-acting insulin versus sliding scale insulin for patients with type 2 diabetes or insulin resistance during cyclic glucocorticoid-containing antineoplastic chemotherapy-a randomized cross-over study","volume":"18","author":"Gerards","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.024_bib63","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13098-025-01585-z","article-title":"Screening and management of hospital hyperglycemia in non-critical patients: a position statement from the Brazilian Diabetes Society (SBD)","volume":"17","author":"Marino","year":"2025","journal-title":"Diabetol Metab Syndr"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.024_bib64","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4158\/EP08331.RAR","article-title":"Glucocorticoid-induced hyperglycemia","volume":"15","author":"Clore","year":"2009","journal-title":"Endocr Pract"},{"issue":"8","key":"10.1016\/j.eprac.2026.01.024_bib65","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1210\/clinem\/dgac277","article-title":"A systematic review supporting the Endocrine Society Clinical Practice guideline for the management of hyperglycemia in adults hospitalized for noncritical illness or undergoing elective surgical procedures","volume":"107","author":"Seisa","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.024_bib66","first-page":"353","article-title":"Assessment of the efficacy and safety of a protocol to manage glucocorticoid-induced hyperglycemia in diabetic patients during hospital stay","volume":"66","author":"Agudo-Tabuenca","year":"2019","journal-title":"Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English Ed)"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.024_bib67","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.diabres.2015.09.015","article-title":"Randomized clinical trial of the efficacy and safety of insulin glargine vs. NPH insulin as basal insulin for the treatment of glucocorticoid induced hyperglycemia using continuous glucose monitoring in hospitalized patients with type 2 diabetes and res","volume":"110","author":"Ruiz de Adana","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.024_bib68","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4158\/EP12256.OR","article-title":"Management of hyperglycemia in diabetic patients with hematologic malignancies during dexamethasone therapy","volume":"19","author":"Gosmanov","year":"2013","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.024_bib69","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1210\/jc.2011-2098","article-title":"Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline","volume":"97","author":"Umpierrez","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.024_bib70","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40842-023-00158-1","article-title":"Treatment of glucocorticoid- induced hyperglycemia in hospitalized patients - a systematic review and meta- analysis","volume":"10","author":"Struja","year":"2024","journal-title":"Clin Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.024_bib71","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2337\/dc10-1407","article-title":"Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery)","volume":"34","author":"Umpierrez","year":"2011","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.eprac.2026.01.024_bib72","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.2337\/dc07-0295","article-title":"Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial)","volume":"30","author":"Umpierrez","year":"2007","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.024_bib73","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/dom.12859","article-title":"Treatment of prednisolone-induced hyperglycaemia in hospitalized patients: insights from a randomized, controlled study","volume":"19","author":"Radhakutty","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.024_bib74","doi-asserted-by":"crossref","first-page":"E355","DOI":"10.1188\/14.ONF.E355-E365","article-title":"Management of steroid-induced hyperglycemia in hospitalized patients with cancer: a review","volume":"41","author":"Brady","year":"2014","journal-title":"Oncol Nurs Forum"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.024_bib75","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1111\/bcp.14403","article-title":"Chimeric antigen receptor T-cell therapy toxicities","volume":"87","author":"Greenbaum","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.024_bib76","first-page":"78","article-title":"Critical care management of chimeric antigen receptor T-cell therapy recipients","volume":"72","author":"Shimabukuro-Vornhagen","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.eprac.2026.01.024_bib77","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.2337\/dc12-1988","article-title":"Randomized study comparing a basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: basal plus trial","volume":"36","author":"Umpierrez","year":"2013","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.024_bib78","doi-asserted-by":"crossref","first-page":"C1822","DOI":"10.1152\/ajpcell.00245.2025","article-title":"GLP-1 receptor agonists in the context of cancer: the road ahead","volume":"328","author":"Miousse","year":"2025","journal-title":"Am J Physiol-Cell Physiol"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.024_bib79","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/dmrr.2486","article-title":"Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment","volume":"30","author":"Hwang","year":"2014","journal-title":"Diabetes Metab Res Rev"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.024_bib80","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1210\/jc.2010-2729","article-title":"Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD","volume":"96","author":"Burt","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.024_bib81","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-028914","article-title":"Management of hyperglycaemia in persons with non-insulin-dependent type 2 diabetes mellitus who are started on systemic glucocorticoid therapy: a systematic review","volume":"9","author":"Tatalovic","year":"2019","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.eprac.2026.01.024_bib82","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1111\/bcp.16082","article-title":"The effect of AZD9567 vs . Prednisolone on glycaemic control in patients with type 2 diabetes mellitus: results from a phase 2a clinical trial","volume":"90","author":"Ambery","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.eprac.2026.01.024_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154246","article-title":"11\u03b2-hydroxysteroid dehydrogenase type 1 inhibitor use in human disease-a systematic review and narrative synthesis","volume":"108","author":"Gregory","year":"2020","journal-title":"Metabolism"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.024_bib84","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1210\/en.2017-00094","article-title":"Separating the anti-inflammatory and diabetogenic effects of glucocorticoids through LXR\u03b2 antagonism","volume":"158","author":"Patel","year":"2017","journal-title":"Endocrinology"},{"issue":"10","key":"10.1016\/j.eprac.2026.01.024_bib85","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.2337\/dc22-0716","article-title":"Continuous glucose monitoring\u2013guided insulin administration in hospitalized patients with diabetes: a randomized clinical trial","volume":"45","author":"Spanakis","year":"2022","journal-title":"Diabetes Care"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26000418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26000418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:26:48Z","timestamp":1781018808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26000418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":85,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1530891X26000418"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.01.024","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucocorticoid-Induced Hyperglycemia in Patients With Cancer: Mechanisms, Clinical Implications, and Management Strategies","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.01.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}